Moderna (MRNA) Short-term Investments (2017 - 2026)

Moderna (MRNA) has reported Short-term Investments for 10 consecutive years, with $3.4 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Short-term Investments fell 11.34% year-over-year to $3.4 billion in Q2 2026; TTM through Jun 2026 was $3.4 billion, a 11.34% decrease from a year earlier, with the FY2025 full-year figure at $3.2 billion, down 37.15% from the prior year.
• Short-term Investments was $3.4 billion for Q2 2026 at Moderna, up from $3.3 billion in the prior quarter.
• Over five years, Short-term Investments peaked at $6.7 billion in Q4 2022 and troughed at $3.2 billion in Q4 2025.
• A 5-year average of $4.8 billion and a median of $5.0 billion in 2022 frame the typical range for Short-term Investments.
• Across the five-year window, Short-term Investments jumped 120.98% in 2022 and plunged 37.15% in 2025, its largest moves.
• Over 5 years, Short-term Investments stood at $6.7 billion in 2022, then dropped by 14.93% to $5.7 billion in 2023, then slipped by 10.51% to $5.1 billion in 2024, then sank by 37.15% to $3.2 billion in 2025, then advanced by 6.59% to $3.4 billion in 2026.
• The last three Short-term Investments figures came in at $3.4 billion (Q2 2026), $3.3 billion (Q1 2026), and $3.2 billion (Q4 2025), per Business Quant data.